ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1558

Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study

Diana Villacis Nunez1, Kaitlin Jones2, Lucie Fan3, Whitney Moore2, Aysha Jabbar2, Matthew Oster4, Preeti Jaggi1 and Sampath Prahalad5, 1Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA, 4Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, 5Emory + Children's Pediatric Institute, Atlanta, GA

Meeting: ACR Convergence 2021

Keywords: COVID-19, Infection, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Infection-related Rheumatic Disease Poster (1530–1564)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes of MIS-C patients treated at our center, and compare these outcomes based on initial management.

Methods: A single center retrospective study was conducted; all patients with MIS-C diagnosis between March 2020 and February 2021 were eligible. Demographic and clinical variables were collected. Patients were divided into 3 groups, based on immunomodulation within the first 24 hours of treatment initiation for patients in the intensive care unit (ICU), or 48 hours for non-ICU patients. The primary outcome was failure of initial therapy defined as need to escalate immunosuppression due to fever, worsening laboratory parameters, and/or lack of improvement/worsening cardiac or non-cardiac findings. Secondary outcomes included duration of fever and vasoactive support, coronary aneurysms/dilation, length of ICU stay, hospital length of stay, readmission, and number of emergency room (ER) visits up to 6 months after discharge. Groups were compared using Kruskal Wallis test for continuous variables and Fisher/Chi-square test for categorical variables, employing R software. P values of ≤0.05 were considered statistically significant.

Results: Two-hundred and thirty-one MIS-C patients were identified. Patients who did not receive immunomodulation (n=5), required biologics within the first 24 hours (n=3), received intravenous immunoglobulin (IVIG) at another center (n=3), or received therapy escalation without meeting the definition of failure of initial therapy (n=4) were excluded. Of the remaining 216 subjects, 116 received IVIG + steroids (Group 1), 31 received IVIG alone (Group 2), and 69 received steroids alone (Group 3) as initial therapy. Maximum initial steroid dose was methylprednisolone/prednisone 2 mg/kg/day. The groups differed in age and racial distribution; patients in group 3 were older (p = 0.02) and less frequently of African American race (p = 0.01). ICU status at the start of therapy was less frequent in group 3 (33.3%) vs group 1 (65.5%) and 2 (71%) (p < 0.001). Rates of initial therapy failure were lowest in group 3 (18.8% vs 30.2% and 54.8% for groups 1 and 2, respectively; p = 0.001). Group 3 had shorter duration of fever (median 5 days vs 6 days in group 1 and 2; p = 0.002), ICU length of stay (median 0 days vs 3 and 5 days for group 1 and 2, respectively; p < 0.001), and total length of stay (median 4 days vs 6 days in groups 1 and 2; p < 0.001). Vasoactive support duration was longer for group 1 (median 1 day vs 0 days for groups 2 and 3; p < 0.001). Coronary outcomes, need for readmission and ER visits post-discharge were similar between groups. All patients survived.

Conclusion: A subgroup of MIS-C patients was successfully treated with steroid monotherapy. This group was older, less frequently African American, likely had milder disease (less frequent ICU status), had lower rates of treatment failure and favorable secondary outcomes. For a subset of MIS-C patients, steroid monotherapy could be a suitable alternative to IVIG. Multivariate analysis controlling for severity and prospective studies are needed to further explore these findings.


Disclosures: D. Villacis Nunez, None; K. Jones, None; L. Fan, None; W. Moore, None; A. Jabbar, None; M. Oster, None; P. Jaggi, None; S. Prahalad, Novartis, 1.

To cite this abstract in AMA style:

Villacis Nunez D, Jones K, Fan L, Moore W, Jabbar A, Oster M, Jaggi P, Prahalad S. Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/therapy-based-outcomes-in-patients-with-multisystem-inflammatory-syndrome-in-children-a-single-center-study/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapy-based-outcomes-in-patients-with-multisystem-inflammatory-syndrome-in-children-a-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences